Professor of Public Policy, University of Southern California
Neeraj Sood, PhD, is professor and vice dean for research at the USC Price School of Public Policy and a founding member the USC Schaeffer Center. His research focuses on pharmaceutical markets, health insurance, economics of innovation, Medicare and global health. He has published over 100 papers in peer-reviewed journals in economics, medicine, and policy, including JAMA, Quarterly Journal of Economics, Journal of Health Economics, Health Affairs, Journal of Policy Analysis and Management and Health Services Research. He has testified frequently on health policy issues and has been on expert committees for the National Academies of Science, Engineering and Medicine. He has received more than $10 million in funding as principal investigator in grants from the National Institutes for Health (NIH), National Science Foundation (NSF) and other prominent funders. His work has been featured in media outlets, including The New York Times, Washington Post, U.S. News and World Report and Scientific American. Sood was the finalist for the 16th and 21st annual National Institute for Health Care Management Health Care Research Award, recognizing outstanding research in health policy. He was also the 2009 recipient of the Eugene Garfield Economic Impact Prize, recognizing outstanding research demonstrating how medical research impacts the economy.
Sood is on the editorial boards of the Journal of Health Economics, Journal of Policy Analysis and Management, and Health Services Research. He is a research associate at the National Bureau of Economic Research and a board member of the American Society of Health Economists. Prior to joining USC, he was a senior economist at RAND and a professor at the Pardee RAND Graduate School.
New federal regulations finalized Nov. 15 require hospitals to make public all the prices they negotiate with insurers and health plans, starting in 2021. The aim is to untangle the hospital marketplace with a wave of...
On the heels of congressional testimony by the CEOs of major drug makers, there are some important things to keep in mind. The U.S. faces a drug pricing crisis in large part because pharmaceuticals are in a golden age of...